---
title: "Chemsex prevalence and associated factors among GBMSM in England, 2022–2025"
id: "medrxiv-22-trends-in-and-factors-associated-with-chemsex-in-a-community-sample-of-gay"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-trends-in-and-factors-associated-with-chemsex-in-a-community-sample-of-gay"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.19.26365930v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Chemsex prevalence and associated factors among GBMSM in England, 2022–2025
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-trends-in-and-factors-associated-with-chemsex-in-a-community-sample-of-gay
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.19.26365930v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators analysed 5,728 responses from the RiiSH annual online cross-sectional survey of **GBMSM** recruited via social networking/dating apps and community partners between 2022 and 2025. - Adjusted prevalence of **chemsex** was reported as 6.1% (2022), 4.2% (2023), 5.1% (2024) and 6.8% (2025), with overall low and broadly stable rates across the period. - Trend estimation used log-binomial regression models; candidate factors were assessed using logistic regression as described by the authors. - The cohort showed higher odds of **chemsex** among participants who were gay (aOR=1.57 vs other orientations), unemployed (aOR=3.08 vs full-time employed), aged 35–59 (versus 16–34), recently using **HIV PrEP** (aOR=3.79), recent **sexual health service (SHS)** users (aOR=2.23), and living with HIV (aOR=3.16). - Authors noted strong associations between **PrEP**/SHS engagement and chemsex, arguing this supports integrating specialist support within SHS settings. - The preprint status and restricted underlying dataset availability were reported; the authors stated ethical approval was granted by UKHSA Research Ethics and Governance Group (R&D 524). - The study team did not report more granular details of drug types, dosing, or event-level sexual risk behaviours in the abstract; those data, if present, are in supplementary material or unavailable for public release according to the authors.
## Clinical Analysis & Structured Key Points
Trends in, and factors associated with, chemsex in a community sample of gay, bisexual, and other men who have sex with men in England, 2022-2025 | medRxiv Skip to main content Trends in, and factors associated with, chemsex in a community sample of gay, bisexual, and other men who have sex with men in England, 2022-2025 View ORCID Profile Jin-Min Yuan , Laura Viviani , Dolores Mullen , Dana Ogaz , Hamish Mohammed doi: https://doi.org/10.64898/2026.10.19.26365930 Jin-Min Yuan 1 Field Epidemiology Training Programme, UKHSA; Immunisation and Vaccine Preventable Diseases Division, UKHSA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jin-Min Yuan For correspondence: jinmin.yuan{at}ukhsa.gov.uk Laura Viviani 2 Blood Safety, Hepatitis, STIs and HIV Division, UKHSA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dolores Mullen 2 Blood Safety, Hepatitis, STIs and HIV Division, UKHSA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dana Ogaz 2 Blood Safety, Hepatitis, STIs and HIV Division, UKHSA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hamish Mohammed 2 Blood Safety, Hepatitis, STIs and HIV Division, UKHSA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background Chemsex, drug use before/during sex to facilitate and enhance the experience, is undertaken by a minority of gay, bisexual and other men who have sex with men (GBMSM), but evidence of chemsex prevalence in England is limited. This study describes trends in chemsex prevalence between 2022-2025 and identifies factors associated with chemsex amongst GBMSM in England. Methods Data from the RiiSH study (2022-2025), an annual online cross-sectional survey of GBMSM recruited through social networking/dating apps and community partners, were analysed. Trends in chemsex prevalence and adjusted prevalence were estimated using log-binomial regression models. The following seven variables were candidate factors associated with chemsex and were assessed through logistic regression: age, sexual orientation, education, employment, HIV status, HIV PrEP use, and sexual health service (SHS) use. Results 5728 GBMSM were included in this study. Adjusted chemsex prevalence varied from 6.1% in 2022 to 4.2% in 2023, 5.1% in 2024 and 6.8% in 2025. Chemsex was more likely in GBMSM who were: gay (aOR=1.57 versus other sexual orientations; 95%CI 1.11-2.29, p=0.01), unemployed (aOR=3.08 versus employed full-time; 95%CI 2.19-4.26, p<0.001); aged 35-59 versus 16-34 years (p<0.001), with recent HIV PrEP use (aOR=3.79 versus no recent use; 95%CI 2.63-5.56, p<0.001), SHS use (aOR=2.23 versus no recent use; 95%CI 1.76-2.83, p<0.001), and living with HIV (aOR=3.16 versus negative/unknown HIV status; 95%CI 2.43-4.09, p<0.001). Conclusions Chemsex prevalence was low and stable between 2022-2025. PrEP and SHS use were associated with chemsex, supporting integration of specialist support services within SHS. Competing Interest Statement The Immunisations and Vaccine Preventable Diseases division at UKHSA has undertaken post-marketing surveillance and regulatory analyses requested by vaccine manufacturers for which cost-recovery charges have been made. No other conflicts of interest have been declared. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval for this study was granted by the United Kingdom Health Security Agency (UKHSA) Research Ethics and Governance Group (reference R&D 524). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The authors cannot make the underlying dataset publicly available for ethical and legal reasons. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 21, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Trends in, and factors associated with, chemsex in a community sample of gay, bisexual, and other men who have sex with men in England, 2022-2025 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Trends in, and factors associated with, chemsex in a community sample of gay, bisexual, and other men who have sex with men in England, 2022-2025 Jin-Min Yuan , Laura Viviani , Dolores Mullen , Dana Ogaz , Hamish Mohammed medRxiv 2026.10.19.26365930; doi: https://doi.org/10.64898/2026.10.19.26365930 Share This Article: Copy Citation Tools Trends in, and factors associated with, chemsex in a community sample of gay, bisexual, and other men who have sex with men in England, 2022-2025 Jin-Min Yuan , Laura Viviani , Dolores Mullen , Dana Ogaz , Hamish Mohammed medRxiv 2026.10.19.26365930; doi: https://doi.org/10.64898/2026.10.19.26365930 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (631) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4936) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (668) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1664) Epidemiology (16148) Forensic Medicine (35) Gastroenterology (1232) Genetic and Genomic Medicine (7198) Geriatric Medicine (747) Health Economics (1087) Health Informatics (5212) Health Policy (1454) Health Systems and Quality Improvement (1811) Hematology (597) HIV/AIDS (1369) Infectious Diseases (except HIV/AIDS) (16416) Intensive Care and Critical Care Medicine (1191) Medical Education (689) Medical Ethics (156) Nephrology (738) Neurology (7479) Nursing (374) Nutrition (1112) Obstetrics and Gynecology (1275) Occupational and Environmental Health (1028) Oncology (3704) Ophthalmology (1078) Orthopedics (401) Otolaryngology (462) Pain Medicine (489) Palliative Medicine (142) Pathology (715) Pediatrics (1841) Pharmacology and Therapeutics (747) Primary Care Research (780) Psychiatry and Clinical Psychology (6059) Public and Global Health (9903) Radiology and Imaging (2495) Rehabilitation Medicine and Physical Therapy (1497) Respiratory Medicine (1262) Rheumatology (655) Sexual and Reproductive Health (793) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)
- [Parenchymal Neuro-Behçet Disease Case Report: Heterogeneous Clinical Presentations](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-parenchymal-neuro-beh-et-disease-with-heterogeneous-clinical-presentations-a.md)
- [Why the U.S. Is Falling Behind England in the Push to Eliminate Hepatitis C](https://medichelpline.com/clinical-feed/stat-news-3-opinion-england-and-other-nations-are-on-the-path-toward-eliminating-hepatitis.md)
- [IeDEA 2026 Site Assessment: Protocol for a Cross-Sectional Survey of HIV Clinics and Service Deliv](https://medichelpline.com/clinical-feed/medrxiv-12-documenting-hiv-service-delivery-and-adoption-of-evidence-based-practices-in.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.